Form 4: EKSO CEO Sells Shares for Tax Obligations
Insider Transaction Report
EKSO Bionics CEO Scott G. Davis sold 23,315 shares of common stock on November 10, 2025, to cover tax withholding obligations related to restricted stock awards.
Summary
- Scott G. Davis, CEO and Director of EKSO BIONICS HOLDINGS, INC. (EKSO), reported a sale of common stock.
- On November 10, 2025, Mr. Davis sold 23,315 shares of EKSO common stock.
- The shares were sold at a price of $4.7990 per share.
- The purpose of the sale was to cover tax withholding obligations incurred upon the vesting and settlement of restricted stock awards.
- These restricted stock awards were originally reported in a Form 4 filed on November 7, 2025.
- The transaction was made pursuant to a Rule 10b5-1(c) plan.
- Following the transaction, Mr. Davis directly beneficially owns 78,777 shares of common stock.
- Additionally, Mr. Davis indirectly beneficially owns 373 shares through a 401(k) plan.
- The reported amounts reflect a 1-for-15 reverse stock split effected by the Issuer on June 2, 2025.
Sentiment
Score: 5
Explanation: The transaction is a routine, pre-planned sale to cover tax obligations related to equity compensation, which is a neutral event and does not reflect a change in management's confidence or the company's operational performance.
Future Outlook
This filing is a historical report of an insider transaction and does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This insider transaction is specific to EKSO Bionics Holdings, Inc. and does not provide broader insights into industry trends or competitive landscape. It represents a routine event for an executive managing their equity compensation.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Policy Adherence | The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). | 11/10/2025 | This indicates adherence to corporate governance best practices for insider transactions, aiming to prevent accusations of trading on material non-public information. |
Stakeholder Impact
- Shareholders: Minimal impact as this is a routine, pre-planned transaction for tax purposes, not indicative of a change in the CEO's outlook on the company's future.
Key Dates
| Date | Description |
|---|---|
| 06/02/2025 | Issuer effected a 1-for-15 reverse stock split of its common stock. |
| 11/07/2025 | Original Form 4 filed reporting restricted stock awards that subsequently vested. |
| 11/10/2025 | Transaction date for the sale of common stock by Scott G. Davis. |
| 11/12/2025 | Date this Form 4 was signed and filed. |
Recommendation
holdThe reported transaction is a routine, pre-planned sale by the CEO to cover tax withholding obligations associated with the vesting of restricted stock awards. Such transactions are common for executives and typically do not reflect a change in the company's fundamental performance or the insider's long-term view of the stock. Therefore, this filing alone does not provide new information that would warrant a change in investment recommendation; a 'hold' stance is appropriate as investors should rely on broader financial performance and strategic updates.
Keywords
EKSO Bionics, Scott Davis, Form 4, Insider Transaction, Stock Sale, CEO, Director, Tax Withholding, Restricted Stock Units, RSU, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.